BACKGROUND: Autoantibodies to 21-hydroxylase (21OH-AA) precede the onset of autoimmune Addison's disease (AD) and are found in 1.5% of individuals with type 1 diabetes mellitus (T1DM). The greatest genetic risk for both disorders is found in the major histocompatibility complex (MHC), suggesting a common pathophysiology between AD and T1DM. Screening for 21OH-AA in newly diagnosed T1DM patients is a valuable prognostic tool, made stronger when MHC genotype is considered. METHODS: The Type 1 Diabetes Genetics Consortium has collected genotype data in T1DM subjects with tissue-specific autoantibody typing. Genotype and phenotype data in individuals positive and negative for 21OH-AA are compared. RESULTS: Major genetic risk for 21OH-AA is in the MHC haplotypes DRB1*04-DQB1*0302 (primarily DRB1*0404) and DRB1*0301-DQB1*0201. Protective effects in class II MHC haplotypes DRB1*0101-DQB1*0501 and DRB1*0701-DQB1*0202 also were detected. There is no difference in the presence of HLA-B15 and little difference in the presence of HLA-B8 (after class II effects are accounted for) in T1DM patients with 21OH-AA compared with known associations (HLA-B8 positive and HLA-B15 negative) in AD. CONCLUSIONS: In 21OH-AA(+) subjects, genetic risk is found mainly in MHC class II haplotypes DR3 and DR4 but not class I alleles (HLA-B8 or HLA-B15). This suggests a difference between autoantibody formation (class II dependent) and progression to overt disease (class I dependent) in AD.
BACKGROUND: Autoantibodies to 21-hydroxylase (21OH-AA) precede the onset of autoimmune Addison's disease (AD) and are found in 1.5% of individuals with type 1 diabetes mellitus (T1DM). The greatest genetic risk for both disorders is found in the major histocompatibility complex (MHC), suggesting a common pathophysiology between AD and T1DM. Screening for 21OH-AA in newly diagnosed T1DM patients is a valuable prognostic tool, made stronger when MHC genotype is considered. METHODS: The Type 1 Diabetes Genetics Consortium has collected genotype data in T1DM subjects with tissue-specific autoantibody typing. Genotype and phenotype data in individuals positive and negative for 21OH-AA are compared. RESULTS: Major genetic risk for 21OH-AA is in the MHC haplotypes DRB1*04-DQB1*0302 (primarily DRB1*0404) and DRB1*0301-DQB1*0201. Protective effects in class II MHC haplotypes DRB1*0101-DQB1*0501 and DRB1*0701-DQB1*0202 also were detected. There is no difference in the presence of HLA-B15 and little difference in the presence of HLA-B8 (after class II effects are accounted for) in T1DM patients with 21OH-AA compared with known associations (HLA-B8 positive and HLA-B15 negative) in AD. CONCLUSIONS: In 21OH-AA(+) subjects, genetic risk is found mainly in MHC class II haplotypes DR3 and DR4 but not class I alleles (HLA-B8 or HLA-B15). This suggests a difference between autoantibody formation (class II dependent) and progression to overt disease (class I dependent) in AD.
Authors: Peter R Baker; Erin E Baschal; Pam R Fain; Priyaanka Nanduri; Taylor M Triolo; Janet C Siebert; Taylor K Armstrong; Sunanda R Babu; Marian J Rewers; Peter A Gottlieb; Jennifer M Barker; George S Eisenbarth Journal: J Clin Endocrinol Metab Date: 2011-05-11 Impact factor: 5.958
Authors: G Gambelunghe; A Falorni; M Ghaderi; S Laureti; C Tortoioli; F Santeusanio; P Brunetti; C B Sanjeevi Journal: J Clin Endocrinol Metab Date: 1999-10 Impact factor: 5.958
Authors: Jennifer M Barker; Akane Ide; Corey Hostetler; Liping Yu; Dongmei Miao; Pamela R Fain; George S Eisenbarth; Peter A Gottlieb Journal: J Clin Endocrinol Metab Date: 2004-10-13 Impact factor: 5.958
Authors: M Rewers; T L Bugawan; J M Norris; A Blair; B Beaty; M Hoffman; R S McDuffie; R F Hamman; G Klingensmith; G S Eisenbarth; H A Erlich Journal: Diabetologia Date: 1996-07 Impact factor: 10.122
Authors: L Yu; K W Brewer; S Gates; A Wu; T Wang; S R Babu; P A Gottlieb; B M Freed; J Noble; H A Erlich; M J Rewers; G S Eisenbarth Journal: J Clin Endocrinol Metab Date: 1999-01 Impact factor: 5.958
Authors: K Badenhoop; P G Walfish; H Rau; S Fischer; A Nicolay; U Bogner; H Schleusener; K H Usadel Journal: J Clin Endocrinol Metab Date: 1995-07 Impact factor: 5.958
Authors: A Falorni; A Nikoshkov; S Laureti; E Grenbäck; A L Hulting; G Casucci; F Santeusanio; P Brunetti; H Luthman; A Lernmark Journal: J Clin Endocrinol Metab Date: 1995-09 Impact factor: 5.958
Authors: Z Gombos; R Hermann; M Kiviniemi; S Nejentsev; K Reimand; V Fadeyev; P Peterson; R Uibo; J Ilonen Journal: Eur J Endocrinol Date: 2007-12 Impact factor: 6.664
Authors: Leonardo P Faverani; Wirley G Assunção; Paulo Sérgio P de Carvalho; Judy Chia-Chun Yuan; Cortino Sukotjo; Mathew T Mathew; Valentim A Barao Journal: PLoS One Date: 2014-03-26 Impact factor: 3.240